

Supplementary Data

Long COVID Manuscript

Author(s): Krystyna Taylor, Matthew Pearson, Sayoni Das, Jason Sardell, Karolina Chocian, Steve Gardner

Date: 13 July 2023

Status: v10



precision**life**.com

PrecisionLife Ltd

Registered Office: Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ
Company No. 08687703 VAT Number GB 172 5125 25

Contents

1	Supplementary File List	3
2	Supplementary Information.....	4
2.1	Sano Genetics Long COVID GOLD Study.....	4
2.2	Genotype Quality Control.....	7
2.1	Gene Annotation Data Sources	7
2.2	Expanded Genotype Analysis.....	8
2.3	Genetic Ancestry Analysis of GOLD study.....	10
2.4	PLINK GWAS Analysis	10
2.5	Combinatorial Analysis.....	11
2.6	Tissue or Cell Expression Profile of Long COVID Genes	12
2.7	Cross-Disease Analysis	14
2.8	Genes Previously Reported in Long COVID Transcriptomics Analysis	17
2.1	Gene Tractability Analysis	18
2.2	Gene Disease Associations.....	20
3	References	22

1 Supplementary File List

1. **Supplementary File 1:** Long COVID GOLD Study - Data Dictionary.xlsx

The data dictionary for the Long COVID GOLD Study is available in this supplementary file.

2. **Supplementary File 2:** Long_COVID_studies_critical_snps.xlsx

List of disease-associated critical SNPs and genes identified by the PrecisionLife platform in the three long COVID cohorts. Additional columns include gene associations from publicly available cell/tissue-specific eQTL and chromatin-interaction (Hi-C) data.

3. **Supplementary File 3:** Pathway enrichment of long COVID Disease Signatures.xlsx

Pathway enrichment analysis results for disease signatures identified in Severe and Fatigue Dominant long COVID cohorts. The enrichment analysis was performed using g:Profiler using Gene Ontology, KEGG, Reactome and WikiPathways as data sources and considering only genes with at least one annotation as background genes. Only significant results ($p < 0.05$) after applying multiple testing correction were reported from the enrichment analysis.

4. **Supplementary File 4:** Severe Cohort Disease signatures associated with symptom-based scores.xlsx


List of disease signatures that are correlated with symptom-based scores such as increase in respiratory, fatigue or mental health change scores prior to and after COVID.

2 Supplementary Information

2.1 Sano Genetics Long COVID GOLD Study

Supplementary Table 1: Scores generated for respiratory, fatigue and mental health symptoms before and after COVID using participant questionnaire responses in the GOLD study.

Symptom-based score	Participant reported scores derived from questionnaire responses	Attributes from questionnaire response used to calculate change in symptoms before and after COVID
Respiratory Change	Change in breathlessness at rest	breathlessness_rest_current - breathlessness_rest_pre_covid
	Change in breathlessness after dressing	breathlessness_dressing_current - breathlessness_dressing_pre_covid
	Change in breathlessness after climbing stairs	breathlessness_climbing_stairs_current - breathlessness_climbing_stairs_pre_covid
Fatigue Change	Change in mobility problems	mobility_problems_severity_now - mobility_problems_severity_pre_covid
	Change in fatigue	fatigue_now - fatigue_pre_covid
	Change in personal care difficulties	personal_care_difficulties_now - personal_care_difficulties_pre_covid
	Change in difficulties to carry on usual activities	usual_activities_difficulty_now - usual_activities_difficulty_pre_covid
	Change in muscle pain or discomfort	muscle_pain_now - muscle_pain_pre_covid
Mental Health Change	Change in anxiety	anxiety_now - anxiety_pre_covid
	Change in depression	depression_now - depression_pre_covid
Total Change	Total change in Respiratory, Fatigue or Mental Health scores	Respiratory score + Fatigue score + Mental Health score




Supplementary Figure 1: Distribution of the 'Total Change' score for all individuals in the GOLD cohort.


PrecisionLife: Supplementary Data

Supplementary Table 2: List of top ranking (n=35) words in the free-text responses of 1,489 (81.41%) individuals in the GOLD study with a COVID diagnosis (n=1,829) along with Severe and Fatigue Dominant cases to the question on other symptoms individuals in the GOLD long COVID cohort have experienced since their illness that was not covered in the questionnaire. The rank of the words reflects their weights based on their incidence within each group.


Rank	All GOLD study individuals with COVID diagnosis (n=1,828)		Severe cases (n=459)		Fatigue Dominant cases (n=477)	
1	Word	Count	Word	Count	Word	Count
2	smell	125	headache	52	pain	62
3	headache	112	tinnitus	48	headache	57
4	pain	98	pain	46	tinnitus	53
5	tinnitus	97	issue	35	issues	37
6	taste	96	POTS	30	symptom	34
7	issue	74	smell	30	POTS	33
8	problem	70	taste	29	smell	33
9	symptom	65	dizziness	29	dizziness	31
10	loss	60	symptom	29	problem	31
11	dizziness	51	problem	28	insomnia	30
12	insomnia	51	tachycardia	27	tachycardia	30
13	POTS	43	skin	26	eye	28
14	skin	42	loss	26	skin	28
15	palpitations	41	insomnia	25	taste	27
16	fatigue	39	eye	24	loss	25
17	hand	39	hand	18	hand	22
18	feeling	36	palpitations	17	palpitations	19
19	severe	36	change	16	heart	17
20	eye	35	tremor	16	change	16
21	tachycardia	34	severe	16	rashes	16
22	still	33	sleep	14	leg	16
23	month	33	heart rate	14	migraine	15
24	muscle	32	hair loss	14	tremor	15
25	sense	32	leg	14	sleep	15
26	time	32	rashes	13	severe	15
27	ear	31	fatigue	13	muscle	14
28	joint pain	31	muscle	13	hair loss	14
29	hair loss	31	brain fog	13	sensitivity	14
30	change	31	sensitivity	13	heart rate	14
31	leg	29	migraine	12	fatigue	14
32	tingling	29	tingling	11	ache	13
33	sleep	29	feel	11	time	13
34	migraine	29	light	11	tingling	13
35	long	28	heart	11	brain fog	13



Supplementary Figure 2: Word clouds for (a) Severe cases, (b) Severe controls, (c) Fatigue Dominant cases and (d) Fatigue Dominant controls generated from free-text responses on other symptoms individuals in the GOLD long COVID cohort have experienced since their illness that was not directly covered in the questionnaire. The size of the words in the word clouds indicate the weights based on their incidence within each subcohort.



Supplementary Figure 3: Sample overlap between the Severe and Fatigue Dominant long COVID cohorts derived from the GOLD study.



Supplementary Figure 4: Distribution of the 'Fatigue Change' and 'Total Change' scores for cases and controls in the Fatigue Dominant long COVID cohort.

2.2 Genotype Quality Control

Appropriate quality control of genotype data was performed using GRAF¹ (Genetic Relationship and Fingerprinting) and PLINK² based on standard quality control procedures to ensure thorough cleaning of the data before it is used for genomic analyses.

This included the following steps:

1. Sample and SNP filtering based on missingness: The filtering for SNPs with missing data (<5%) was followed by filtering of individuals with missing data (<5%) using PLINK.
2. Minor Allele Frequency (MAF) filtering of SNPs: The genotype data would be filtered to exclude SNPs with MAF < 5% using PLINK.
3. Hardy-Weinberg Equilibrium (HWE) filtering: HWE filtering was performed on controls with $p < 10^{-10}$ using PLINK.
4. Heterozygosity filtering: Samples with extreme (very high or very low) heterozygosity were removed.
5. Sample filtering based on relatedness: GRAF-rel³ was used to identify duplicates and closely related subjects in the dataset. After identification of close relatives, only one representative of each closely related family pairs was retained.
6. Sex discrepancy of individuals: Samples that have discrepancies between the sex recorded in the dataset and their sex based on absence/presence of a Y chromosome were removed.

2.3 Gene Annotation Data Sources

Supplementary Table 3: Example public data sources used for annotating genes in the PrecisionLife platform.

Annotation Type	Data Source(s)
Genomic Context	Ensembl ⁴ , Entrez ⁵ , gnomAD ⁶ , HaploReg ⁷ , ClinVar ⁸ , Variant Effect Predictor ⁹ , RegulomeDB ¹⁰
Encoded Protein Structure and Function	Uniprot ¹¹ , InterPro ¹² , PDBe-KB ¹³
SNP-Disease or Trait Association	dbSNP ¹⁴ , GWAS Catalog ¹⁵ , PharmGKB ¹⁶ , Open Targets Genetics ¹⁷
Gene-Disease or Trait Association	PubMed ¹⁸ , PubChem ¹⁹ , Open Targets ²⁰ , Mouse Genome Informatics ²¹ , Human Phenotype Ontology ²² , OMIM ²³
Gene Tissue/Cell Expression	GTEX ²⁴ , Human Protein Atlas ²⁵ , Expression Atlas ²⁶

Pathways, Interactions or MoA	Reactome ²⁷ , KEGG ²⁸ , Gene Ontology Annotation ²⁹ , PANTHER ³⁰ , WikiPathways ³¹ , IntAct ³² , STRING ³³ , BioGRID ³⁴ , PubMed ¹⁸
Safety / Toxicology	International Mouse Phenotyping Consortium ³⁵ , Tox21 ³⁶ , eTox ³⁷ , HeCaToS ³⁸ , Open Targets ²⁰
Drugs and Chemical Compounds	ChEMBL ³⁹ , DrugBank ⁴⁰ , PHAROS ⁴¹ , PubChem ¹⁹ , ProbeMiner ⁴² , PDBe-KB ¹³ , ClinicalTrials.gov ⁴³ , Unichem ⁴⁴ , OpenFDA ⁴⁵

2.4 Comparison of Long COVID with ME/CFS

Supplementary Table 4: List of 39 SNPs identified in disease signatures associated with long COVID in the Severe and Fatigue Dominant long COVID cohorts that can be linked to 9 genes identified in a combinatorial analysis of UK Biobank ME/CFS patients. 13 SNPs are shown in **bold** that were identified as critical SNPs in each long COVID cohort.

Gene	Severe cohort	Fatigue-Dominant cohort
AKAP1		rs2270278
ATP9A		rs1205693
ATP9A		rs2147338
ATP9A		rs6067922
ATP9A	rs6096573	rs6096573
ATP9A		rs6126313
ATP9A	rs77771672	rs77771672
ATP9A	rs2426361	
CDON		rs4937076
CLOCK		rs62303689
GPC5	rs1536620	rs1536620
GPC5		rs16946160
GPC5	rs17267214	rs17267214
GPC5	rs2183606	rs2183606
GPC5		rs35616509
GPC5	rs6492567	rs6492567
GPC5		rs7319083
GPC5		rs950725
GPC5		rs9560999
GPC5		rs9589601
GPC5	rs2149066	
GPC5	rs462954	
GPC5	rs59625704	
GPC5	rs9301839	
GPC5	rs9523723	
GPC5	rs9560843	
GPC5	rs989236	
INSR	rs10427021	rs10427021
INSR	rs6510976	rs6510976
INSR	rs7317941	rs7317941
INSR	rs8110533	rs8110533
INSR	rs10426094	

INSR	rs4804103	
PHACTR2	rs7742964	rs7742964
PHACTR2		rs9376793
PHACTR2		rs9496708
PHACTR2	rs10979	
SLC15A4	rs11059915	rs11059915
USP6NL	rs11257114	

2.5 Expanded Genotype Analysis

Supplementary Table 5: Descriptions of the seven categories that can potentially be assigned to critical SNPs during expanded genotype analyses.


Category	Observed association of critical SNP minor allele with disease
Universally causative	Consistently associated with increased odds of disease relative to the homozygous wildtype genotype.
Universally protective	Consistently associated with decreased odds of disease relative to the homozygous wildtype genotype.
SNP-specific causative effect	Associated with increased odds of disease only when it co-occurs with the minor allele of at least one interacting SNP. Associated with decreased odds of disease in patients who are homozygous for the wildtype alleles of the interacting SNPs.
SNP-specific protective effect	Associated with decreased odds of disease only when it co-occurs with the minor allele of at least one SNP. Associated with increased odds of disease in patients who are homozygous for the wildtype alleles of the interacting SNPs.
Combination-specific causative effect	Associated with increased odds of disease only when it co-occurs with a specific combination of genotypes at multiple interacting SNPs. Associated with decreased odds of disease in other patients.
Combination-specific protective effect	Associated with decreased odds of disease only when it co-occurs with a specific combination of genotypes at multiple interacting SNPs. Associated with increased odds of disease in other patients.
Ambiguous	No consistent association with disease risk across expanded genotype signature comparisons. May reflect a highly complex biological interaction, a “false positive” disease signature, or stochastic noise in the data that obscures true biological relationships.

2.6 Genetic Ancestry Analysis of GOLD study

Supplementary Table 6: Genetic ancestry distribution of samples within the two long COVID cohorts in the GOLD study.

	Severe Long COVID n = 1,323		Fatigue Dominant Long COVID n = 1,386	
	Cases (n=459)	Controls (n=864)	Cases (n=477)	Controls (n=909)
Genetic ancestry [n] S Asian: South Asian E Asian: East Asian O Asian: Other Asian AA: African American	Europe: 426 S Asian: 14 E Asian: 1 African: 1 AA: 1 Hispanic1: 7 Hispanic: 0 O Asian: 1 Other: 8	Europe: 794 S Asian: 23 E Asian: 9 African: 6 AA: 12 Hispanic1: 5 Hispanic2: 2 O Asian: 9 Other: 3	Europe: 443 S Asian: 15 E Asian: 0 African: 1 AA: 3 Hispanic1: 6 Hispanic2: 0 O Asian: 1 Other: 8	Europe: 838 S Asian: 23 E Asian: 10 African: 6 AA: 11 Hispanic1: 7 Hispanic2: 2 O Asian: 9 Other: 3

2.7 PLINK GWAS Analysis




Supplementary Figure 5: Manhattan plots generated using PLINK of genome-wide p -values of association for the (a) Severe cohort ($n = 1,323$ where cases = 459 and controls = 864) and (b) Fatigue Dominant cohort ($n = 1,386$ where cases = 477 and controls = 909). The horizontal blue and red lines represent the genome-wide significance values of $p < 1 \times 10^{-5}$ and $p < 5 \times 10^{-8}$ respectively.

2.8 Combinatorial Analysis


Supplementary Table 7: The number of disease signatures (SNP combinations) that pass ancestry confounder analysis and the proportion of non-European cases (based on genetic ancestry) in each long COVID cohort.

Long COVID Cohort	Disease Signatures that pass ancestry confounder analysis	Non-European Case Count (% of non-European samples)
Severe	1,188 (100%)	33 (32.35%)
Fatigue Dominant	1,306 (91.0%)	34 (32.4%)

2.9 Tissue or Cell Expression Profile of Long COVID Genes



Supplementary Figure 6: Clustered heatmap showing tissue expression profiles from GTEx²⁴ for 64 out of 73 long COVID genes identified in the GOLD study with expression information.



Supplementary Figure 7: Clustered heatmap showing single cell expression profiles from Human Protein Atlas²⁵ for 49 out of 73 long COVID genes identified in the GOLD study with expression information.

2.10 Cross-Disease Analysis

Supplementary Table 8: Disease-associated genes identified for each indication group that have genetic evidence reported in Open Targets²⁰ (version 23.02, released in February 2023). Only genes with target-disease genetic association score > 0.9 out of 1.0 have been used.

Indication groups	No. of disease-associated genes in indication group (Open Targets target-disease)	Overlap with long COVID genes (n = 73)
Neurodegenerative disease (EFO:0005772)	170	0
Mental or behavioral disease (EFO:0000677)	97	1
Cardiovascular disease (EFO:0000319)	107	0
Gastrointestinal disease (EFO:0010282)	80	0
Autoimmune disease (EFO:0005140)	40	1
Metabolic disease (EFO:0000589)	410	1

Supplementary Table 9: List of diseases included under each indication group based on Experimental Factor Ontology (EFO) ontology⁴⁶.

Indication group (EFO term)	Diseases included under each indication group (direct descendants in the EFO ontology)
Neurodegenerative disease (EFO:0005772)	Marchiafava-Bignami Disease secondary Parkinson disease Primary progressive aphasia tauopathy motor neuron disease inherited neurodegenerative disorder cerebellar degeneration human prion disease infantile bilateral striatal necrosis diffuse cerebral and cerebellar atrophy - intractab... eye degenerative disorder demyelinating disease neuroaxonal dystrophy synucleinopathy
Mental or behavioral disease (EFO:0000677)	Atypical progressive supranuclear palsy Right temporal lobar atrophy Classical progressive supranuclear palsy CADASIL pathological gambling post-concussion syndrome internalizing disorder stress-related disorder dysphoria visuospatial impairment somatoform disorder

PrecisionLife: Supplementary Data

	gender identity disorder Sleep Disorder Kluver-Bucy syndrome agnosia anxiety disorder substance withdrawal syndrome developmental disorder of mental health psychosis occupation-related stress disorder eating disorder mood disorder drug dependence nervousness decreased attention adjustment disorder alcohol-induced mental disorder cognitive disorder drug-induced mental disorder
Cardiovascular disease (EFO:0000319)	vascular disease heart disease cardiovascular neoplasm congenital anomaly of cardiovascular system autoimmune disorder of cardiovascular system
Gastrointestinal disease (EFO:0010282)	Genetic digestive tract tumor Genetic intestinal disease chemotherapy-induced gastrointestinal mucositis ventral hernia stomach rupture stomach diverticulum lingual thyroid immunoproliferative small intestinal disease Chilaiditi Syndrome enterocolitis colon diverticulum mouth disease intestinal volvulus gastric outlet obstruction gastric antral vascular ectasia Salivary Gland Acinic Cell Carcinoma Intestinal Type Adenocarcinoma Hyperplastic Polyp Gastric Diffuse Large B-Cell Lymphoma Duodenal Gastrin-Producing Neuroendocrine Tumor Digestive System Adenoma gastrointestinal toxicity hepatobiliary disease gastrointestinal ulceration, recurrent, with dysfunctional platelets small intestine enteropathy flatulence stomach disease pancreas disease disease of peritoneum foreign body in gastrointestinal tract intestinal disease

PrecisionLife: Supplementary Data

	splenic disease trichuriasis staphyloenterotoxemia paratyphoid fever oesophagostomiasis necatoriasis hymenolepiasis gastrointestinal tuberculosis echinostomiasis dicrocoeliasis coccidiosis ascaridiasis ascariasis rotavirus infection upper digestive tract disorder digestive system neuroendocrine neoplasm gastrointestinal polyp neoplasm of oropharynx gastroesophageal disease congenital enteropathy due to enteropeptidase deficiency Cronkhite-Canada syndrome peptic ulcer disease digestive system cancer diarrheal disease autoimmune disorder of gastrointestinal tract benign digestive system neoplasm
Autoimmune disease (EFO:0005140)	Susac Syndrome orofacial granulomatosis malacoplakia monogenic diabetes Eosinophilia-Myalgia Syndrome CNS demyelinating autoimmune di... STAT3 gain of function latent autoimmune diabetes in a... autoimmune bullous skin disease reactive arthritis Guillain-Barre syndrome autoimmune thrombocytopenic pur... autoimmune thyroid disease cryoglobulinemia Autoimmune Hepatitis Granulomatosis with Polyangiiti... Myasthenia gravis anti-neutrophil antibody associ... Vitiligo cutaneous lupus erythematosus Behcet's syndrome inflammatory bowel disease antiphospholipid syndrome juvenile idiopathic arthritis Sjogren syndrome rheumatoid arthritis systemic lupus erythematosus
Metabolic disease	Tumor Lysis Syndrome

PrecisionLife: Supplementary Data

(EFO:0000589)	hyperamylasemia lipodystrophy hemochromatosis acquired metabolic disease... lactic acidosis x-linked warfarin sensitivity metabolic toxicity mineral metabolism disease... glucose metabolism disease... methylmalonic aciduria (c...) hepatic methionine adenopathy hyperprolactinemia gout Hypertriglyceridemia diabetic retinopathy xanthoma nutritional disorder diabetic nephropathy metabolic syndrome disorder of organic acid ... steroid metabolism disease... disorder of acid-base bal... pyrimidine metabolism dis... purine metabolism disease porphyrin metabolism dise... carbohydrate metabolism d... hyperlipoproteinemia bilirubin metabolism dise... disorder of glycosylation hyperlipidemia proteostasis deficiencies inborn errors of metaboli... steroid dehydrogenase def... hypoalphalipoproteinemia developmental anomaly of ... familial thyroid dyshormo... chondrocalcinosis xanthinuria glutaric aciduria
---------------	---

2.11 Genes Previously Reported in Long COVID Transcriptomics Analysis

Supplementary Table 10: Table showing long COVID genes identified in the GOLD study by the PrecisionLife platform that were reported to be differentially expressed (adjusted *p* value < 0.05) by Thomas et. al⁴⁷ in different cell types (ModelVariant = 'Serology_AGM'). Upregulated genes have positive log2 fold change (logFC) and downregulated genes have negative logFC.

Gene	Long COVID cohort	Cell Type	log2 fold change (logFC)	Adjusted <i>p</i> value
ABCA9	Fatigue Dominant	NK cells resting	6.338	0.028
DRG1	Fatigue Dominant	T cells CD8	-0.566	0.025
ETS1	Severe	T cells CD4 memory resting	1.796	0.000

PrecisionLife: Supplementary Data

<i>ETS1</i>	Severe	T cells CD8	-1.224	0.031
<i>ETS1</i>	Severe	Neutrophils	-1.563	0.006
<i>JAKMIP2</i>	Fatigue Dominant	T cells CD4 memory resting	2.142	0.048
<i>JAKMIP2</i>	Fatigue Dominant	Neutrophils	-2.330	0.049
<i>KLF12</i>	Fatigue Dominant	T cells CD4 memory resting	2.072	0.000
<i>KLF12</i>	Fatigue Dominant	T cells gamma delta	-1.386	0.036
<i>KLF12</i>	Fatigue Dominant	Neutrophils	-1.519	0.025
<i>LYRM2</i>	Fatigue Dominant	T cells CD4 memory resting	0.637	0.049
<i>LYRM2</i>	Fatigue Dominant	T cells CD8	-0.840	0.021
<i>LYRM2</i>	Fatigue Dominant	Neutrophils	-0.842	0.016
<i>LYRM2</i>	Fatigue Dominant	T cells CD8	-1.093	0.002
<i>PPP1R16B</i>	Severe	T cells CD4 memory resting	1.785	0.004
<i>PPP1R16B</i>	Severe	Neutrophils	-1.805	0.010
<i>RAB31</i>	Severe	T cells CD8	1.054	0.032
<i>RRAS2</i>	Severe	T cells CD4 memory resting	1.730	0.010
<i>RRAS2</i>	Severe	Neutrophils	-1.725	0.025
<i>RRAS2</i>	Severe	T cells CD8	-1.941	0.006
<i>SNX9</i>	Severe	T cells CD4 memory resting	1.007	0.028
<i>SPON1</i>	Fatigue Dominant	Plasma cells	-7.862	0.021
<i>SPPL3</i>	Fatigue Dominant	T cells CD8	1.120	0.002
<i>SPPL3</i>	Fatigue Dominant	NK cells resting	1.023	0.026
<i>SPPL3</i>	Fatigue Dominant	T cells CD8	0.944	0.016
<i>SPPL3</i>	Fatigue Dominant	T cells gamma delta	0.849	0.040
<i>TCF4</i>	Severe	B cells memory	2.066	0.046
<i>TENM3</i>	Severe	T cells follicular helper	6.741	0.028

2.12 Gene Tractability Analysis

Supplementary Table 11: Genes identified in the long COVID study with their tractability as drug targets using annotations from OpenTargets²⁰ and other annotations from Human Protein Atlas²⁵ and PHAROS⁴¹.

Gene	Long COVID Cohort	Protein class	PHAROS target classification	Small molecule Tractability	Small molecule Clinical	Antibody Tractability	Drugs	Active Compounds
<i>GUCY1A2</i>	Severe/Fatigue	Enzyme	Tclin	0.3	1	0	8	595
<i>CETP</i>	Severe/Fatigue	Transporter	Tchem	1	0.7	1	4	555
<i>TLR4</i>	Severe	Enzyme,	Tchem	0.3	0.7	1	10	506

PrecisionLife: Supplementary Data

		Transporter						
TCF4	Severe/Fatigue	Transcription factor	Tbio	0	0	0	0	334
MYO3B	Severe/Fatigue	Enzyme	Tchem	0.3	0	0	0	245
LARGE1	Severe/Fatigue		Tbio	0	0	0	0	99
PCSK2	Severe/Fatigue	Enzyme	Tchem	0	0	0.7	2	8
PDE6C	Severe/Fatigue	Enzyme	Tclin	0.3	1	0.7	2	1
CLCN6	Severe/Fatigue		Tchem	0	0	0.7	0	2
SOX5	Severe/Fatigue	Transcription factor	Tbio	0	0	0	0	2
PRODH	Severe/Fatigue	Enzyme	Tbio	0	0	0	2	0
RRAS2	Severe/Fatigue	RAS pathway related protein	Tbio	0.7	0	0.7	0	0
ADIPOQ	Severe	Transporter	Tbio	0	0	1	0	0
ADGRA3	Severe/Fatigue	G-protein coupled receptor	Tbio	0	0	0	0	1
SNX9	Severe/Fatigue		Tbio	0.7	0	0.3	0	0
PPP1R16B	Severe/Fatigue		Tbio	0	0	1	0	0
DSCAML1	Severe		Tbio	0	0	1	0	0
SORCS2	Severe/Fatigue		Tbio	0	0	0.7	0	0
APCDD1	Severe/Fatigue		Tbio	0	0	0.7	0	0
ETS1	Severe	Transcription factor	Tbio	0.7	0	0	0	0
SGCG	Severe/Fatigue		Tbio	0	0	0.3	0	0
GPC6	Severe/Fatigue		Tbio	0	0	0.3	0	0
RAB31	Severe/Fatigue		Tbio	0	0	0.3	0	0
MAPK9	Fatigue/Severe	Enzyme	Tchem	1	0.7	0	6	877
TNIK	Fatigue/Severe	Enzyme	Tchem	1	0	0	1	765
CDK14	Fatigue/Severe	Enzyme	Tchem	0.3	0.7	0.3	0	258
HPN	Fatigue/Severe	Enzyme	Tchem	0	0	1	4	179
POR	Fatigue	Enzyme	Tbio	0.3	0	0	13	30
PDE4D	Fatigue/Severe	Enzyme	Tclin	1	1	1	26	4
SLC12A1	Fatigue/Severe	Transporter	Tclin	0.3	1	0.3	19	0
DRG1	Fatigue/Severe		Tbio	0	0	0	0	4
NLGN1	Fatigue/Severe	Transporter	Tbio	0.3	0	1	0	0
RRBP1	Fatigue		Tbio	0	0	0	1	0
TNS1	Fatigue		Tbio	0	0	0.7	0	0
ACOT12	Fatigue	Enzyme, Transporter	Tbio	0.7	0	0	0	0
SPON1	Fatigue/Severe		Tbio	0.7	0	0	0	0
SYN3	Fatigue/Severe		Tbio	0.7	0	0	0	0
PLXNA2	Fatigue/Severe		Tbio	0	0	0.3	0	0
CNTN4	Fatigue/Severe		Tbio	0	0	0.3	0	0
PTPRD	Fatigue/Severe	Enzyme	Tbio	0	0	0.3	0	0

SPPL3	Fatigue/Severe	Enzyme	Tbio	0	0	0.3	0	0
WWOX	Fatigue/Severe		Tbio	0	0	0.3	0	0

2.13 Gene Disease Associations

Supplementary Table 12: Genes with prior association to type 2 diabetes in OpenTargets^{Error! Reference source not found.} database.

Long COVID Cohort	Gene	Known association to type 2 Diabetes (OpenTargets)
Severe	ADIPOQ	Scientific literature, Animal models
Severe	ZMIZ1	Genetic association
Severe	PDE6C	Drugs approved and/or in clinical development for indication
Severe	SGCG	Genetic association
Severe	RAB31	Genetic association
Severe	NOL4	Genetic association
Severe	ETS1	Genetic association
Fatigue Dominant	TNS1	Genetic association
Fatigue Dominant	NLGN1	Genetic association
Fatigue Dominant	PITPNC1	Genetic association
Fatigue Dominant	EIF4ENIF1	Genetic association

PrecisionLife: Supplementary Data

Supplementary Table 13: 19 pathways that are significantly enriched in the 73 long COVID genes that were also significantly enriched in at least one of the following indication groups - neurodegenerative, mental or behavioral, cardiovascular, gastrointestinal, autoimmune and metabolic disorders.

GO Biological process	Long COVID (p value)	Autoimmune disease (p value)	Cardiovascular disease (p value)	Gastrointestinal disease (p value)	Mental or behavioural disease (p value)	Metabolic disease (p value)	Neurodegenerative disease (p value)
anatomical structure development	0.022	0.001673	1.01E-14	0.00237	3.13E-17	6.84E-06	1.05E-09
cell adhesion	0.026	2.60E-05	0.000181				
cell communication	0.039	1.76E-06	8.95E-07	0.032485	0.000232		0.009076
cell differentiation	0.008	0.000395	1.39E-09	0.004574	1.71E-13		3.31E-06
cell-cell signaling	0.021	0.594388	9.09E-05	0.001775	1.77E-06		0.000316
chemical synaptic transmission	0.048		0.037426		1.03E-06		3.88E-06
dendrite self-avoidance	0.045						
filopodium assembly	0.045						
foam cell differentiation	0.014					0.02689	
glial cell migration	0.033				0.001138		
modulation of chemical synaptic transmission	0.008		0.003983		2.40E-08		0.004787
nervous system development	0.008		5.16E-05	0.023153	2.17E-22	9.30E-06	1.88E-18
neurogenesis	0.008		0.000267	0.036673	7.46E-18		2.72E-12
neuron cell-cell adhesion	0.042						
positive regulation of cell differentiation	0.034	0.000192	0.000622	0.0085	1.75E-05		
positive regulation of hormone metabolic process	0.039						
positive regulation of protein dephosphorylation	0.027						
presynapse assembly	0.028						
regulation of biological quality	0.004		6.66E-12	0.000111	1.41E-05	1.41E-06	0.000444
regulation of cell communication	0.006	2.31E-05	3.25E-06	6.50E-05	1.24E-05		
regulation of cellular component biogenesis	0.028		0.000692		0.007012		0.000388
regulation of signaling	0.006	2.28E-05	2.07E-05	6.17E-05	1.18E-05		
regulation of trans-synaptic signaling	0.008		0.004034		2.44E-08		0.004861
response to epinephrine	0.039		0.010242				
response to stimulus	0.029	2.53E-06	3.65E-08	0.04138	8.65E-07	0.011387	0.01398
synaptic membrane adhesion	0.01						

synaptic vesicle clustering	0.045						
-----------------------------	-------	--	--	--	--	--	--

3 References

1. Jin, Y., Schaffer, A.A., Feolo, M., Holmes, J.B. and Kattman, B.L., 2019. GRAF-pop: a fast distance-based method to infer subject ancestry from multiple genotype datasets without principal components analysis. *G3: Genes, Genomes, Genetics*, 9(8), pp.2447-2461.
2. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., De Bakker, P.I., Daly, M.J. and Sham, P.C., 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *The American journal of human genetics*, 81(3), pp.559-575.
3. Jin, Y., Schäffer, A.A., Sherry, S.T. and Feolo, M., 2017. Quickly identifying identical and closely related subjects in large databases using genotype data. *PLoS One*, 12(6), p.e0179106.
4. Martin, F.J., Amode, M.R., Aneja, A., Austine-Orimoloye, O., Azov, A.G., Barnes, I., Becker, A., Bennett, R., Berry, A., Bhai, J. and Bhurji, S.K., 2023. Ensembl 2023. *Nucleic Acids Research*, 51(D1), pp.D933-D941.
5. Brown, G.R., Hem, V., Katz, K.S., Ovetsky, M., Wallin, C., Ermolaeva, O., Tolstoy, I., Tatusova, T., Pruitt, K.D., Maglott, D.R. and Murphy, T.D., 2015. Gene: a gene-centered information resource at NCBI. *Nucleic acids research*, 43(D1), pp.D36-D42.
6. Koch, L., 2020. Exploring human genomic diversity with gnomAD. *Nature Reviews Genetics*, 21(8), pp.448-448.
7. Ward, L.D. and Kellis, M., 2016. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic acids research*, 44(D1), pp.D877-D881.
8. Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, K., Liu, C. and Lyoshin, V., 2020. ClinVar: improvements to accessing data. *Nucleic acids research*, 48(D1), pp.D835-D844.
9. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thormann, A., Flicek, P. and Cunningham, F., 2016. The ensembl variant effect predictor. *Genome biology*, 17(1), pp.1-14.
10. Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., Kasowski, M., Karczewski, K.J., Park, J., Hitz, B.C., Weng, S. and Cherry, J.M., 2012. Annotation of functional variation in personal genomes using RegulomeDB. *Genome research*, 22(9), pp.1790-1797.
11. UniProt Consortium, 2019. UniProt: a worldwide hub of protein knowledge. *Nucleic acids research*, 47(D1), pp.D506-D515.
12. Paysan-Lafosse, T., Blum, M., Chuguransky, S., Grego, T., Pinto, B.L., Salazar, G.A., Bileschi, M.L., Bork, P., Bridge, A., Colwell, L. and Gough, J., 2023. InterPro in 2022. *Nucleic Acids Research*, 51(D1), pp.D418-D427.
13. Varadi, M., Berrisford, J., Deshpande, M., Nair, S.S., Gutmanas, A., Armstrong, D., Pravda, L., Al-Lazikani, B., Anyango, S., Barton, G.J. and Berka, K., 2020. PDBe-KB: a community-driven resource for structural and functional annotations. *Nucleic Acids Research*, 48(D1), pp.D344-D353.
14. Bhagwat, M., 2010. Searching NCBI's dbSNP database. *Current protocols in bioinformatics*, 32(1), pp.1-19.
15. Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E. and Suveges, D., 2019. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic acids research*, 47(D1), pp.D1005-D1012.
16. Barbarino, J.M., Whirl-Carrillo, M., Altman, R.B. and Klein, T.E., 2018. PharmGKB: a worldwide resource for pharmacogenomic information. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 10(4), p.e1417.
17. Ghousaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E.M., Hercules, A., Fumis, L., Miranda, A., Carvalho-Silva, D., Buniello, A. and Burdett, T., 2021. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. *Nucleic acids research*, 49(D1), pp.D1311-D1320.
18. Roberts, R.J., 2001. PubMed Central: The GenBank of the published literature. *Proceedings of the National Academy of Sciences*, 98(2), pp.381-382.
19. Kim, S., Thiessen, P.A., Cheng, T., Yu, B., Shoemaker, B.A., Wang, J., Bolton, E.E., Wang, Y. and Bryant, S.H., 2016. Literature information in PubChem: associations between PubChem records and scientific articles. *Journal of cheminformatics*, 8, pp.1-15.

PrecisionLife: Supplementary Data

20. Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M. and Baker, J., 2021. Open Targets Platform: supporting systematic drug–target identification and prioritisation. *Nucleic acids research*, 49(D1), pp.D1302-D1310.
21. Eppig, J.T., Smith, C.L., Blake, J.A., Ringwald, M., Kadin, J.A., Richardson, J.E. and Bult, C.J., 2017. Mouse Genome Informatics (MGI): resources for mining mouse genetic, genomic, and biological data in support of primary and translational research. *Systems Genetics: Methods and Protocols*, pp.47-73.
22. Köhler, S., Gargano, M., Matentzoglu, N., Carmody, L.C., Lewis-Smith, D., Vasilevsky, N.A., Danis, D., Balagura, G., Baynam, G., Brower, A.M. and Callahan, T.J., 2021. The human phenotype ontology in 2021. *Nucleic acids research*, 49(D1), pp.D1207-D1217.
23. Amberger, J.S., Bocchini, C.A., Schietecatte, F., Scott, A.F. and Hamosh, A., 2015. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. *Nucleic acids research*, 43(D1), pp.D789-D798.
24. GTEx Consortium, 2020. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*, 369(6509), pp.1318-1330.
25. Digre, A. and Lindskog, C., 2021. The human protein atlas—spatial localization of the human proteome in health and disease. *Protein Science*, 30(1), pp.218-233.
26. Papatheodorou, I., Fonseca, N.A., Keays, M., Tang, Y.A., Barrera, E., Bazant, W., Burke, M., Füllgrabe, A., Fuentes, A.M.P., George, N. and Huerta, L., 2018. Expression Atlas: gene and protein expression across multiple studies and organisms. *Nucleic acids research*, 46(D1), pp.D246-D251.
27. Jassal, B., Matthews, L., Viteri, G., Gong, C., Lorente, P., Fabregat, A., Sidiropoulos, K., Cook, J., Gillespie, M., Haw, R. and Loney, F., 2020. The reactome pathway knowledgebase. *Nucleic acids research*, 48(D1), pp.D498-D503.
28. Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Kawashima, S., Okuda, S., Tokimatsu, T. and Yamanishi, Y., 2007. KEGG for linking genomes to life and the environment. *Nucleic acids research*, 36(suppl_1), pp.D480-D484.
29. Huntley, R.P., Sawford, T., Mutowo-Meullenet, P., Shybitsyna, A., Bonilla, C., Martin, M.J. and O'Donovan, C., 2015. The GOA database: gene ontology annotation updates for 2015. *Nucleic acids research*, 43(D1), pp.D1057-D1063.
30. Mi, H., Muruganujan, A., Ebert, D., Huang, X. and Thomas, P.D., 2019. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic acids research*, 47(D1), pp.D419-D426.
31. Martens, M., Ammar, A., Riutta, A., Waagmeester, A., Slenter, D.N., Hanspers, K., A. Miller, R., Digles, D., Lopes, E.N., Ehrhart, F. and Dupuis, L.J., 2021. WikiPathways: connecting communities. *Nucleic acids research*, 49(D1), pp.D613-D621.
32. Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F., Chen, C., Duesbury, M., Dumousseau, M., Feuermann, M., Hinz, U. and Jandrasits, C., 2012. The IntAct molecular interaction database in 2012. *Nucleic acids research*, 40(D1), pp.D841-D846.
33. Szklarczyk, D., Gable, A.L., Nastou, K.C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N.T., Legeay, M., Fang, T., Bork, P. and Jensen, L.J., 2021. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic acids research*, 49(D1), pp.D605-D612.
34. Oughtred, R., Rust, J., Chang, C., Breitkreutz, B.J., Stark, C., Willem, A., Boucher, L., Leung, G., Kolas, N., Zhang, F. and Dolma, S., 2021. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. *Protein Science*, 30(1), pp.187-200.
35. Muñoz-Fuentes, V., Cacheiro, P., Meehan, T.F., Aguilar-Pimentel, J.A., Brown, S.D., Flenniken, A.M., Flicek, P., Galli, A., Mashhadi, H.H., Hrabé de Angelis, M. and Kim, J.K., 2018. The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation. *Conservation genetics*, 19, pp.995-1005.
36. Richard, A.M., Huang, R., Waidyanatha, S., Shinn, P., Collins, B.J., Thillainadarajah, I., Grulke, C.M., Williams, A.J., Lougee, R.R., Judson, R.S. and Houck, K.A., 2020. The Tox21 10K compound library: collaborative chemistry advancing toxicology. *Chemical Research in Toxicology*, 34(2), pp.189-216.
37. Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C.H., Pastor, M., Wichard, J. and Sanz, F., 2014. The eTOX data-sharing project to advance in silico drug-induced toxicity prediction. *International journal of molecular sciences*, 15(11), pp.21136-21154.
38. Verheijen, M., Sarkans, U., Wolski, W., Jennen, D., Caiment, F. and Kleinjans, J., 2022. Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compounds. *Scientific data*, 9(1), p.699.

PrecisionLife: Supplementary Data

39. Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B. and Overington, J.P., 2012. ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic acids research*, 40(D1), pp.D1100-D1107.
40. Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z. and Assempour, N., 2018. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic acids research*, 46(D1), pp.D1074-D1082.
41. Kelleher, K.J., Sheils, T.K., Mathias, S.L., Yang, J.J., Metzger, V.T., Siramshetty, V.B., Nguyen, D.T., Jensen, L.J., Vidović, D., Schürer, S.C. and Holmes, J., 2023. Pharos 2023: an integrated resource for the understudied human proteome. *Nucleic Acids Research*, 51(D1), pp.D1405-D1416.
42. Antolin, A.A., Tym, J.E., Komianou, A., Collins, I., Workman, P. and Al-Lazikani, B., 2018. Objective, quantitative, data-driven assessment of chemical probes. *Cell chemical biology*, 25(2), pp.194-205.
43. Anand, V., Cahan, A. and Ghosh, S., 2017. Clinical Trials. Gov: A Topical Analyses. AMIA Summits on Translational Science Proceedings, 2017, p.37.
44. Chambers, J., Davies, M., Gaulton, A., Hersey, A., Velankar, S., Petryszak, R., Hastings, J., Bellis, L., McGlinchey, S. and Overington, J.P., 2013. UniChem: a unified chemical structure cross-referencing and identifier tracking system. *Journal of cheminformatics*, 5(1), p.3.
45. Kass-Hout, T.A., Xu, Z., Mohebbi, M., Nelsen, H., Baker, A., Levine, J., Johanson, E. and Bright, R.A., 2016. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. *Journal of the American Medical Informatics Association*, 23(3), pp.596-600.
46. Malone, J., Adamusiak, T., Holloway, E. and Parkinson, H., 2009. Developing an application ontology for annotation of experimental variables—Experimental Factor Ontology. *Nature Precedings*, pp.1-1.
47. Thompson, R.C., Simons, N.W., Wilkins, L., Cheng, E., Del Valle, D.M., Hoffman, G.E., Cervia, C., Fennessy, B., Mouskas, K., Francoeur, N.J. and Johnson, J.S., 2023. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. *Nature medicine*, 29(1), pp.236-246.